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Introduction Prostate cancer is forth most common diagnosed tumors in Malaysian male. 
The use of a self-reported, quality of life assessment is important for clinical 
practice, care taker and researcher to evaluate the level of quality of life. The 
aim of this study was to measure the internal consistency of the translated 
Malay Language EORTC QLQ-C30 and EORTC PR-25 questionnaires among 
prostate cancer patient at National University of Malaysia hospital in Kuala 
Lumpur, Malaysia.  
Methods This was a cross sectional study conducted between July 2017 and Dec 2017. 
The respondent comprised of 110 Malaysian prostate cancer patients who were 
under follow up at Urology and Oncology Clinic. Sets of translated Malay 
language EORTC QLQ C30 and EORTC PR-25 consisted of functional, 
symptom and global health status domains were administered to assess their 
quality of life. 
Results The translated questionnaires were acceptable by 110 respondents. Cronbach`s 
α coefficient result were 0.913 (EORTC QLQ-C30) and 0.829 (EORTC PR-
25) respectively suggested that this instrument had good internal consistency. 
Conclusions Our study confirmed that translated Malay language EORTC QLQ-C30 and 
QLQ-PR25 questionnaires are acceptable, reliable and valid instrument to be 
used among Malaysian prostate cancer patients. 
Keywords Quality of Life - EORTC QLQ C30 - EORTC PR-25 - Prostate Cancer - Malay 
Language. 
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INTRODUCTION 
Prostate cancer is one of the most frequently 
diagnosed tumor in the Western and many Asian 
developed countries.1 In Malaysia, prostate cancer 
reported as third most common type of cancer in 
male with 1,807 new cases in 2018 and accounts for 
8.8% of all cancer cases after respiratory system and 
colorectal cancer.2 The incidence of prostate cancer 
is low in men under 50 years of age. The rate 
increases sharply with increment of age and is 
highest in the oldest age group. With increasing life 
expectancy, westernized diet, improvement of 
medical technologies in screening and treatment the 
mortality among prostate cancer patients were 
decreased significantly.  
As a one of the common malignancy in 
elderly male, prostate cancer contributed to the 
burden of health care which may include the cost of 
screening, treatment and follow up, hospital stay, 
psychological anxiety or depression and even 
palliative care.  
Quality of life in cancer patient may be 
affected by physical function, emotional, role, social 
and also financial constrain.4 It is defined as the 
ability to perform everyday activities that reflect 
physical, psychological, and social well-being; and 
patient satisfaction with levels of functioning and 
control of the disease. The use of self-reported, 
quality of life assessment has become a valuable tool 
in clinical practice and research to determine the 
status of the cancer patients according to their stage 
of disease and the treatment received. Besides that, 
the quality of life tool play significant role in guiding 
the clinician to offer treatment to the cancer patients. 
The European Organization for Research and 
treatment of Cancer (EORTC) had come out with 
the set of questionnaires to assess the quality of life 
among cancer patients in general and also for 
specific cancer types. As for prostate cancer, 
multiple center studies had used the tool to assess 
patients` quality of life.5 
Generally, treatment offered to cancer 
patients were determined by their stage of 
malignancy. These treatment may lead to urinary, 
incontinence, bowel and sexual function changes. 
Although many studies had concluded that prostate 
cancer has better prognosis with good survival rates 
compared to other malignancies1, the quality of life 
aspect such as their role, social and financial 
difficulties must also be focused, as different type of 
treatment may cause different adverse effect to 
patient.6-8  
Many studies reported that quality of life 
differed among patients receiving different type of 
treatment such as radical prostatectomy, radiation 
therapy and brachytherapy. In a study of 580 
patients with localized prostate cancer reported that 
urine incontinence and sexual function were better 
after external beam radiation therapy.9 While 
another study among 212 prostate cancer patients 
who underwent brachytherapy reported low global 
health scores lower functional-scale and symptom 
scores in the brachytherapy group compared with 
those who underwent radical prostatectomy.10 
In Malaysia, there was no study assessing 
quality of life among prostate cancer patients using 
EORTC questionnaires identified. The main 
objective of the study was to evaluate and measure 
the internal consistency of psychometric properties 
of the EORTC Quality of Life questionnaires QLQ-
C30 and QLQ-PR25 in prostate cancer patients and 
to compare with validation studies done in other 
countries. This secondary objective was to measure 
the score of quality of life related to different stages 
and type of treatment in prostate cancer disease. 
 
METHODS 
Design and Sample Characteristics 
This was a descriptive cross sectional study done in 
National University of Malaysia Hospital. The study 
was conducted between July 2017 and Dec 2017. 
The respondents consisted of prostate cancer 
patients who followed up at the Urology Clinic and 
Oncology Clinic. A universal sampling was done to 
get the prostate cancer patients during biweekly 
urology clinic follow-up every Monday and Friday.  
All prostate cancer diagnosed patients who came to 
follow up clinic were offered to participate in the 
study. The minimum numbers of respondent were 
calculated based on ratio of questions and 
respondent to one question to minimum three 
respondents per set of questionnaire18 which require 
90 respondents for EORTC QLQ C30 and 75 
respondents for EORTC QLQ-PR25 questionnaires. 
The inclusion criteria were Malaysian citizen, able 
to read and understand the Malay language 
translated questionnaires and willing to sign consent 
form prior to study. Patient with multiple 
malignancies disease were excluded in this study. 
There were no limitations of the age, stage of disease 
and type of treatment among patients. The list of 
prostate cancer patients were first confirmed by 
tracking the result of Trans-Rectal Ultrasound 
guided (TRUS) biopsy from the medical record. 
This study was approved by ethics committee of the 
study hospital as it was part of thesis study (FF-249-
2017) measuring survival and quality of life of the 
prostate cancer patients.  
 
Instrument 
All prostate cancer patients in the study were given 
two complete sets of Malay language translated of 
EORTC QLQ-C30 (version 3.0) and EORTC PR-25 
questionnaires. The questionnaires were already 
translated to Malay Language as per protocol 
produced.11 The EORTC QLQ-C30 set consist of 30 
items with three main domains of Functionality, 
Symptom and Global Health Status while EORTC 
PR-25 consist of 25 questions with functionality and 
symptom domains (Table 1). The patients and the 
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relatives were first explained regarding the purpose 
of study, requirement and scale of the questionnaires 
used and given time from their registration at the 
follow up clinic till end of the clinic session. Any 
difficulty, confusion and help required during 
completion of the questionnaire were noted during 
session. In order to ensure the completion of answer, 
all patients were assisted to answer the missing 
answer questions and asked for their comment on 
understanding the questionnaires. Other patient 
related clinical information were collected during 
the interview and reviewing of patient`s medical 
record after clinic session been done. 
 
Table 1 Domain structure of EORTC QLQ-30 and EORTC-PR 25 questionnaires 
 
Domain Number of Questions 
EORTC QLQ-30  
Functional Scale  
Physical 5 
Role 2 
Emotional 4 
Cognitive 2 
Social 2 
Symptom Scale  
Fatigue 3 
Nausea & Vomiting 2 
Pain 2 
Dyspnoe 1 
Insomnia 1 
Appetite Loss 1 
Constipation 1 
Diarrhea 1 
Financial Difficulties 1 
Global Health Status  2 
Functional Scale  
Sexual Activity 2 
Sexual functioning 4 
Symptom Scale  
Urinary Symptom 8 
Bowel Symptom 4 
Treatment-Related Symptom 6 
Incontinence-Aid Symptom 1 
Statistical analyses 
All collected data were analysed using Statistical 
Package for Social Science (SPSS) version 21. All 
descriptive categorical data were presented in 
frequency and percentage while continuous data 
calculated in mean and standard deviation. 
Descriptive statistics were used to describe socio-
demographics and clinical related information. The 
score for each domain in the EORTC QLQ-C30 and 
PR-25 were calculated and scaled according to the 
scoring manual.12 Raw scores were transformed into 
a scale ranging from 0 to 100 with higher scores 
indicate better functioning on the functional 
subscales and the global quality of life scale, and 
more symptoms on the symptom subscales. 
Cronbach`s α coefficient was used to measure the 
internal consistency of each domain.13 Cronbach`s α 
of 0.70 was set as an acceptable level of reliability13-
14. Inter item correlation is performed to find out the 
relationship between items in each variable. If all the 
scales have statistically significant inter item 
correlations, it means the scales are reliable and 
measure the same variable in question. One–way 
Anova test method was used to measure the 
difference between stages and type of treatment 
received by prostate cancer patients. A p-value of 
less than 0.05 was considered as statistically 
significant. 
 
RESULTS 
 
Table 2 Sociodemographic and clinical characteristics of the 110 prostate cancer patients 
 
 Stage I Stage II Stage III Stage IV 
 n = 8 n = 73 n = 24 n = 5 
Age (Years)     
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< 60 0 (0.0) 2 (2.7) 1 (4.2) 0 (0.0) 
≥ 60 – 69  2 (25.0) 24 (32.9) 3 (12.5) 2 (40.0) 
≥ 70 – 79  2 (25.0) 26 (35.6) 13 (54.2) 1 (20.0) 
≥ 80 – 89  3 (37.5) 21 (28.8) 7 (29.1) 2 (40.0) 
≥ 90  1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Mean (S.D) 78.6 (7.7) 73.6  (8.3) 75.0 (6.8) 75.4 (8.4) 
Race     
Malay 4 (50.0) 29 (39.8) 6 (25.0) 1 (20.0) 
Chinese 3 (37.5) 40 (54.8) 15 (52.5) 4 (80.0) 
Indian 1 (12.5) 4 (5.4) 3 (12.5) 0 (0.0) 
Marital Status     
Single 0 (0.0) 0 (0.0) 1 (4.2) 0 (0.0) 
Married 6 (75.0) 60 (82.2) 18 (75.0) 5 (100.0) 
Widowed/Divorced 2 (25.0) 13 (17.8) 5 (20.8) 0 (0.0) 
Education Level     
Primary and Below 2 (25.0) 36 (49.3) 13 (54.2) 2 (40.0) 
Secondary 5 (62.5) 29 (39.7) 10 (41.7) 2 (40.0) 
Tertiary 1 (12.5) 8 (11.0) 1 (4.1) 1 (20.0) 
Income     
< RM 1 000 1 (12.5) 15 (20.5) 3 (12.5) 2 (40.0) 
≥ RM 1000 – RM 
3000 
4 (50.0) 27 (37.0) 13 (54.1) 1 (20.0) 
≥ RM 3000 – RM 
5000 
2 (25.0) 21 (28.8) 4 (16.7) 2 (40.0) 
≥ RM5000 1 (12.5) 10 (13.7) 4 (16.7) 0 (0.0) 
Gleason Score     
4 0 (0.0) 2 (2.7) 1 (4.1) 0 (0.0) 
5 0 (0.0) 1 (1.6) 1 (4.1) 0 (0.0) 
6 3 (37.5) 27 (37.0) 6 (25.0) 1 (20.0) 
7 1 (12.5) 20 (27.3) 7 (29.2) 2 (40.0) 
8 1 (12.5) 5 (6.8) 4 (16.7) 1 (20.0) 
9 3 (37.5) 17 (23.2) 4 (16.7) 1 (20.0) 
10 0 (0.0) 1 (1.4) 1 (4.2) 0 (0.0) 
 
Treatment      
Active Surveillance  3 (37.5) 3 (4.1) 0 (0.0) 0 (0.0) 6 (5.5) 
Hormonal Therapy 2 (25.0) 29 (39.7) 5 (20.8) 0 (0.0) 36 (32.7) 
Surgical Intervention 1 (12.5) 7 (9.6) 1 (4.2) 0 (0.0) 9 (8.2) 
Combination Therapy 2 (25.0) 34 (46.6) 18 (75.0) 5 (100.0) 59 (53.6) 
         *data describe as n (%) 
 
Description of sociodemographic and 
clinical information of the prostate cancer patients 
are displayed in Table 2. A total of 110 respondents 
with prostate cancer were willing to participate in 
the study. All patients were able to complete the 
questionnaires in the time frame given with only five 
patients required assistant on translated English to 
Malay language words of “inkontinens” 
(incontinence), “buku lali” (ankle), “ereksi” 
(erection) and “ejakulasi” (ejaculation). Most of the 
prostate cancer patients were in the Stage II (66.6%) 
followed by Stage III (21.8%), Stage I (7.3%) and 
Stage IV (4.5%). Level of education had showed 
that most prostate cancer patients had attended at 
least secondary education level (90%) and more than 
half of them earned less than RM 3000 monthly. 
Gleason score reported 33.6% prostate cancer 
patients with Gleason 6 and 27.2% with Gleason 7. 
In the distribution of treatment offered to patients 
showed that only 5.5% prostate cancers opted or 
selected for active surveillance and watchful waiting 
based on their condition, 32.7% on hormonal 
therapy, 8.2% for surgical intervention and more 
than half had undergone combination therapy 
(53.6%). 
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Group Comparisons 
 
Table 3 EORTC QLQ-30 and EORTC-PR 25 questionnaires scoring of 110 prostate cancer patients based on 
stage 
 
Domain Stage I 
n=8 
Mean (± S.D) 
Stage II 
n=73 
Mean (± S.D) 
Stage III 
n=24 
Mean (± S.D) 
Stage IV 
n=5 
Mean (± S.D) 
ANOVA p-value* 
EORTC QLQ-C30       
Functional Scale       
Physical 75.83 (17.43) 53.70 (25.07) 59.44 (25.17) 66.67 (20.00) 2.359 0.076 
Role 81.25 (24.30) 54.57 (32.79) 61.81 (23.30) 53.33 (32.06) 2.032 0.114 
Emotional 79.17 (17.25) 69.06 (25.85) 72.57 (24.01) 78.33 (22.51) 0.612 0.608 
Cognitive 70.83 (19.42) 59.59 (26.05) 68.06 (24.53) 63.33 (21.73) 1.008 0.392 
Social 72.92 (28.08) 61.19 (33.80) 68.06 (30.66) 70.00 (34.16) 0.554 0.647 
Symptom Scale       
Fatigue 33.38 (20.57) 51.46 (26.68) 42.58 (25.52) 40.00 (30.02) 1.747 0.162 
Nausea & 
Vomiting 
6.25 (8.63) 20.09 (22.39) 12.50 (17.20) 3.33 (7.45) 2.453 0.067 
Pain 27.08 (17.68) 42.24 (29.14) 34.03 (24.81) 26.67 (32.49) 1.401 0.247 
Dyspnea 8.33 (15.43) 22.83 (26.57) 9.72 (15.48) 6.67 (14.91) 2.840 0.041 
Insomnia 33.33 (39.84) 47.95 (34.24) 48.61 (34.02) 40.00 (27.89) 0.523 0.667 
Appetite Loss 16.67 (17.82) 35.62 (27.40) 26.39 (29.45) 33.33 (47.14) 1.494 0.221 
Constipation 4.17 (11.79) 26.48 (28.31) 20.83 (25.66) 40.00 (27.87) 3.086 0.030 
Diarrhea 0.00 (0.00) 20.09 (25.90) 19.44 (27.66) 6.67 (14.91) 1.905 0.133 
Financial 
Difficulties 
37.5 (27.81) 45.25 (36.16) 37.50 (35.86) 46.67 (44.72) 0.358 0.783 
Global Health Status  76.04 (13.68) 72.26 (13.03) 44.10 (11.39) 33.33 (19.54) 4.205 0.007 
EORTC PR-25       
Functional Scale       
Sexual Activity 64.58 (30.13) 81.96 (18.58) 80.56 (21.79) 66.67 (26.35) 2.414 0.071 
Sexual functioning 57.29 (24.57) 74.88 (19.10) 65.63 (23.86) 53.33 (32.06) 3.566 0.017 
Symptom Scale       
Urinary Symptom 36.98 (26.95) 44.79 (19.20) 44.79 (19.20) 34.27 (10.79) 0.609 0.611 
Bowel Symptom 9.37 (9.38) 16.32 (19.27) 16.32 (19.27) 3.33 (4.56) 1.607 0.192 
Treatment-related 
Symptom 
17.33 (10.04) 20.14 (17.86) 20.17 (17.86) 21.13 (19.80) 0.624 0.601 
1. The score range from 0 – 100 with a higher score representing higher functioning level and more symptoms. 
2. *significant value at the level p < 0.05 
 
The results showed that there were 
significant differences in global health status, sexual 
function and in symptom of dyspnea and 
constipation in the different stages of cancer while 
scores based on type of treatment showed significant 
difference in constipation symptom. Incontinence 
symptom was excluded during analysis as the 
patients with incontinence aid were less than 10%.  
Global Health status or Quality of Life domain 
showed no significant difference in the different 
type of treatment received by the patients.  
 
Table 4 EORTC QLQ-30 and EORTC-PR 25 questionnaires scoring of 110 prostate cancer patients based on type 
of treatment 
 
Domain Active 
Surveillance  
 
n=6 
Mean  
(± S.D) 
Hormonal 
Therapy 
 
n=36 
Mean  
(± S.D) 
Surgical 
Intervention 
 
n=9 
Mean  
(± S.D) 
Combination 
Therapy 
 
n=59 
Mean  
(± S.D) 
ANOVA p-value* 
EORTC QLQ-C30       
Functional Scale       
Physical 76.67 (22.21) 56.85 (27.30) 60.00 (16.99) 68.08 (22.06) 1.441 0.235 
Role 66.67 (29.81) 55.56 (23.99) 59.26 (29.00) 54.96 (24.30) 0.238 0.870 
Emotional 81.94 (19.31) 75.00 (23.99) 59.26 (20.17) 58.47 (28.09) 1.506 0.217 
Cognitive 69.44 (19.48) 61.57 (26.67) 57.41 (22.22) 69.21 (25.81) 0.292 0.831 
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Social 83.33 (27.88) 62.50 (33.42) 61.11 (32.27) 63.28 (37.22) 0.757 0.521 
Symptom Scale       
Fatigue 57.17 (27.76) 45.37 (27.78) 53.08 (21.36) 47.27 (25.32) 0.484 0.694 
Nausea & 
Vomiting 
57.41 (38.76) 15.28 (21.22) 14.81 (15.47) 19.21 (21.62) 1.286 0.283 
Pain 2.78 (6.80) 40.28 (27.42) 35.18 (24.22) 38.42 (28.07) 0.102 0.959 
Dyspnea 36.11 (40.02) 14.81 (21.74) 25.93 (22.22) 18.08 (24.23) 0.854 0.468 
Insomnia 22.22 (40.37) 47.22 (34.16) 55.56 (33.33) 47.46 (33.45) 1.250 0.295 
Appetite Loss 27.78 (25.09) 35.19 (23.06) 29.63 (26.06) 31.07 (28.27) 0.229 0.876 
Constipation 16.67 (18.26) 13.87 (23.06) 44.44 (37.28) 24.86 (26.67) 3.662 0.015 
Diarrhea 5.56 (13.61) 14.81 (23.15) 22.22 (28.86) 20.34 (26.99) 0.915 0.437 
Financial 
Difficulties 
22.22 (27.22) 39.81 (36.36) 29.63 (35.14) 49.15 (35.21) 1.823 0.147 
Global Health 
Status  
73.61 (13.35) 63.89 (18.15) 62.96 (20.46) 68.08 (22.06) 0.649 0.585 
EORTC PR-25       
Functional Scale       
Sexual Activity 69.44 (37.14) 77.77 (20.70) 85.18 (17.57) 81.07 (19.68) 0.865 0.462 
Sexual 
functioning 
54.17 (27.76) 71.99 (23.83) 74.07 (19.74) 70.83 (20.39) 1.252 0.295 
Symptom Scale       
Urinary 
Symptom 
40.27 (18.19) 36.81 (20.03) 42.59 (18.61) 45.76 (19.35) 1.600 0.194 
Bowel 
Symptom 
15.28 (16.17) 11.11 (15.81) 24.07 (19.29) 18.36 (17.49) 2.032 0.114 
Treatment-
related 
Symptom 
27.78 (20.18) 19.29 (16.35) 22.84 (18.52) 24.39 (18.34) 0.778 0.509 
1. The score range from 0 – 100 with a higher score representing higher functioning level and more symptoms.  
2. *significant value at the level p < 0.05 
 
Validity of EORTC QOL Instruments 
 
Table 5 Reliability test of the EORTC QLQ-30 and PR-25  
 
Questionnaires No. of Item Cronbach`s α Inter-Item Correlation 
EORTC QLQ-30 30 0.913 0.18-0.67 
Functional scale 15 0.905 0.41-0.72 
Symptom scale 13 0.878 0.47-0.68 
Global Health status 2 0.937 0.891 
EORTC PR-25 25 0.829 0.17-0.53 
Functional scale 6 0.787 0.23-0.70 
Symptom scale 19 0.869 0.22-0.62 
 
The reliability test, Cronbach`s α 
coefficient result for all domains in both sets of 
questionnaires showed more than 0.70 (Table 5) 
with 0.913 (QLQ-C30) and 0.829 (EORTC-PR25) 
respectively. Inter-item in the general EORTC 
QLQ-C30 had showed moderate (0.40-0.60) and 
high correlation (0.891) while item in the EORTC 
PR-25 showed weak to moderate correlation (0.20-
0.70).  
 
DISCUSSION 
In this study, we measured the internal consistency 
of Malay language translated version of EORTC 
QLQ-C30 and EORTC PR-25 questionnaires on 
prostate cancer among patients who undergone 
follow up at Urology and Oncology clinic of 
Malaysia National University hospital. The study 
showed that the acceptability and understanding of 
the translated Malay language questionnaires were 
very good although the respondent comprised of 
three different races.  
The Cronbach`s α of more than 0.70 were 
good in both questionnaires showed that this set of 
questionnaire were acceptable to be used in 
Malaysia14. Cronbach`s α indicate that the item in 
this questionnaires fit together conceptually. 
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Although some author suggested that coefficient 
alpha should be more than 0.90, DeVellis had 
contended that the value of more than 0.90 showed 
redundancies and indicated that the tools should be 
shortened.12-14 The patients were able to complete 
the sets of questionnaires without extensive help. 
Sociodemographic features showed that our patients 
age and level of education slightly difference from 
few study done in European countries and 
Taiwan.5,15-17 The findings where both domain scales 
for EORTC-PR-25 showed low to moderate 
correlation comparing to the core EORTC-QLQ 
C30 was consistent with other studies.16-17  The result 
of group comparison showed a higher score in the 
EORTC-QLQ-C30 functional group compared to 
the newly developed EORTC-PR-25 questionnaire. 
Similar findings were reported by studies done 
among Spanish and Taiwanese population.16-17  
Comparing result of internal consistency of 
questionnaires, this study had similarity in the value 
of Cronbach`s α with other studies conducted in 
different countries such in a Polish population with 
0.898 (EORTC QL-C30) and 0.870 (EORTC QLQ-
PR25), Spanish population with 0.720 to 0.860 and 
Taiwanese population with 0.800 (EORTC QLQ-
C30).16-17 
As prostate cancer had been shown to have 
very good survival rate and prognosis, the difference 
in the score of functional and symptom between 
stages of disease were not significantly different.1 
There were no significant differences of scores in the 
functional domains of physical, role, emotional, 
cognitive and social function among prostate cancer 
either they were diagnosed in early or advanced 
stages. The study also showed that there were no 
significant differences between types of treatment 
with the functionality of the prostate cancer patients.  
 
CONCLUSION 
Our internal consistency study confirmed that 
translated Malay language EORTC QLQ-C30 and 
QLQ-PR25 questionnaires are reliable with 
Cronbach`s alpha 0.91 and 0.83 respectively, can be 
used to measure quality of life in Malaysian patients 
with prostate cancer. However, more comparison 
study should be conducted to ensure it could be used 
in a bigger scale study. 
 
ACKNOWLEDGEMENT 
We would like to acknowledge the surgery and 
oncology department for giving permission to do the 
study. 
 
DECLARATION 
Authors declared that there were no conflicts of 
interest in this study 
 
 
 
REFERENCES 
1.  The international Agency for Research on 
Cancer. Prostate Cancer Incidence and 
Mortality Worldwide in 2008.Summary. 
Globocan, 2010. 
2.  World Health Organization (2018) 
www.who.int/cancer/country-
profiles/mys. 
3.  Gerard CCL (2003). Cancer in Malaysia -
there is light at the end of the tunnel. Med 
J Malaysia, 58, 632-5. 
4.  World Health Organization. (1978). The 
constitution of the world health 
organization. Geneva: WHO. 
5.  Van Andel G, Bottomley A, Fossa S et al 
(2008) An international field study of the 
EORTC QLQ-PR 25: a questionnaire for 
assessing the health-related quality of life 
of patients with prostate cancer. Eur J 
cancer 44: 2418-2424. 
6.  Efficace F, Bottomley A, van Andel G. 
(2003) Health related quality of life in 
prostate carcinoma patients: a systematic 
review of randomized controlled trials. 
Cancer; 97:377-88. 
7. Litwin MS. (2003). Quality of life 
following definitive therapy for localized 
prostate cancer: potential impact of 
multiple therapies. Curr Opin Urol; 
13:152-6. 
8.  Lubeck DP, Grossfeld GD, Carroll PR. 
(2001) The effect of androgen deprivation 
therapy on health-related quality of life in 
men with prostate cancer. Urology; 58(2 
Supp 1):94-100. 
9.  Litwin MS, Gore JL, Kwan L, et al. (2007) 
Quality of life after surgery, external beam 
irradiation, or brachytherapy for early-
stage prostate cancer. Cancer; 109:2239-
47. 
10.  Wyler SF, Engeler DS, Seelentag W, et al. 
(2009) Health-related quality of life after 
radical prostatectomy and low-dose-rate 
brachytherapy for localized prostate 
cancer. Urol Int; 82:17-23.  
11. Cull A, Sprangers M, Bjordal K, Aaronson 
N, on behalf of the EORTC Quality of Life 
Study Group. (1998) EORTC Quality of 
Life Study Group Translation Procedure. 
EORTC, Brussels, ISBN: 2-930064-15-3. 
12.  Fayers P, Aaronson N, Bjordahl K, et al: 
(2001) The EORTC QLQ-C30 scoring 
Manual. 3rd edition. European 
Organization for Cancer Research and 
Treatment of Cancer, Brussels. 
13.  Cronbach LJ (1951) Coefficient alpha and 
the internal structure of tests. 
Psychometrika 16:297. 
International Journal of Public Health Research Vol 10 No 1 20, pp (1158-1165) 
1165 
14. DeVellis R.F (2003). Scale development: 
Theory and application (2nd Ed). Thousand 
Oaks, CA: SAGE. 
15.  Arraras JI, Villafranca E, de la Vega FA, et 
al. (2008) The EORTC quality of life 
questionnaires QLQ-C30 (version 3.0). 
Validation study for Spanish prostate 
cancer patients. Arch Esp Urol; 61:949-54. 
16.  Arraras JI, Villafranca E, de la Dega FA, et 
al. (2009) The EORTC quality of life 
questionnaire for patient with prostate 
cancer: EORTC QLQ-PR25.Validation 
study for Spanish patients. Clin Trans 
Oncol 11:160-4. 
17.  W.C Chie, C.C Yu, H.J Yu. (2010). 
Reliability and Validity of the Taiwan 
Chinese Version of the EORTC QLQ-
PR25 in Assessing Quality of Life of 
Prostate Cancer Patients. Urol Sci 
21(3):118-125. 
18. Costello A.B & Osborne J.W (2005). Best 
practice in Exploratory factor Analysis: 
Four Recommendation for Getting the 
Most from Your Analysis. Practical 
Assesment Research & Evaluation. 
10(7):1-9. 
